Brief History of Remedica, a leading pharmaceutical company in the European Union
Remedica's History

2017
2017
- Nevalan®, a drug for acid related disorders, Entevirem®, an antiviral for systemic use, Rezavir®, an antiviral for systemic use, and Bradirem®, a cardiac therapy were registered successfully in Cyprus.
- Remedica elected as the best Company in the Ascendis Health Group of Companies
2016
2016
Remedica became part of the Johannesburg-listed healthcare conglomerate Ascendis Health Ltd. As part of this development, Remedica integrated with the Ascendis Health Pharma-Med division and became an important and integral part of a stronger, international player.
2015
2015
- Remedica won a place in the final top 10 best export companies across Europe (Ruban d’Honneur) at the European Business Awards.
- The company was successfully inspected by the Iranian Authorities (IFDA)
2014
2014
- The company was successfully inspected by the Japanese Authorities (PMDA)
- Remedica received its 8th Export Award for Industry
2013
2013
- Remedica’s new oncology facility begun operations. Imarem® (Imatinib), an anti-neoplastic agent, was registered in Cyprus
- Successful inspection by the Brazilian Authorities (ANVISA)
- The company has been included by the IN BUSINESS Magazine in its list of the fifty most socially responsible companies in Cyprus
- Remedica announced the Pattihis Family Scholarship for the MSc Management Degree in the Department of Management Science and Innovation at University College London (UCL), UK
- Remedica sponsored the Cyprus University of Technology “Open Access Author Fund” so that it’s library can offer open access to students to publish their research.